Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.130
-0.030 (-2.59%)
At close: Mar 17, 2026, 4:00 PM EDT
1.170
+0.040 (3.54%)
After-hours: Mar 17, 2026, 5:18 PM EDT
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$41,280
Profits / Employee
-$846,677
Market Cap
131.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Vor Biopharma | 154 |
| Rani Therapeutics Holdings | 106 |
| Precision BioSciences | 67 |
| Spero Therapeutics | 32 |
| Ovid Therapeutics | 23 |
FATE News
- 13 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewsWire
- 4 months ago - Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 5 months ago - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy - GlobeNewsWire
- 7 months ago - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 9 months ago - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - GlobeNewsWire